Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390843 · ClinicalTrials.gov registry record · Phase 1
Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT02390843 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 13 participants.
The verdict
NCT02390843, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a Phase I trial with new experimental drugs such as simvastatin in combination with topotecan and cyclophosphamide in the hopes of finding a drug that may work against tumors that have come back or that have not responded to standard therapy. This study will define toxicity of high dose simvastatin in combination with topotecan and cyclophosphamide and evaluate for cholesterol levels and IL6/STAT3 pathway changes as biomarkers of patient response.
Interventions
- DRUG Cyclophosphamide
- DRUG Topotecan
- DRUG Simvastatin
- DRUG Myeloid growth factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-02 |
| Est. Completion | 2019-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02390843
The ClinicalTrials.gov registry entry for NCT02390843 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02390843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02390843 about?
NCT02390843 is a clinical study titled "Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors". This is a Phase I trial with new experimental drugs such as simvastatin in combination with topotecan and cyclophosphamide in the hopes of finding a drug that may work against tumors that have come back or that have not responded to standard therapy. This study will define toxicity of high dose simv...
What is the current status of trial NCT02390843?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2015-02. Estimated completion is 2019-09-22.
What interventions are being tested in trial NCT02390843?
The interventions under investigation include: Cyclophosphamide (DRUG), Topotecan (DRUG), Simvastatin (DRUG), Myeloid growth factor (DRUG).
Who is sponsoring clinical trial NCT02390843?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.